Search Results - "Bollen, Andy"

PATH-30. CLINICAL OUTCOMES AND PREDICTIVE BIOMARKERS FOR IDH-WILDTYPE GLIOBLASTOMAS DEVELOPING HYPERMUTATION FOLLOWING TEMOZOLOMIDE TREATMENT by Young, Jacob, Lucas, Calixto-Hope, Al-Adli, Nadeem, Gupta, Rohit, Morshed, Ramin, Wu, Jasper, Ravindranathan, Ajay, Shai, Anny, Oberheim-Bush, Nancy Ann, Taylor, Jennie, de Groot, John, Villanueva-Meyer, Javier, Pekmezci, Melike, Perry, Arie, Bollen, Andy, Theodosopoulos, Philip, Aghi, Manish, Chang, Edward, Hervey-Jumper, Shawn, Raleigh, David, Diaz, Aaron, Costello, Joseph, Clarke, Jennifer, Butowski, Nicholas, Phillips, Joanna, Chang, Susan, Berger, Mitchel, Solomon, David

“…Current standard of care for IDH-wildtype glioblastoma (GBM) includes maximal safe resection, adjuvant radiation, and chemotherapy with the alkylating agent…”
Get full text

Magnetic resonance imaging as a surrogate measure for histological sub-chronic endpoint in a neonatal rat stroke model by Derugin, Nikita, Dingman, Andra, Wendland, Michael F., Fox, Christine, Bollen, Andy, Vexler, Zinaida S.

“…Introduction: It is becoming increasingly recognized that CNS immaturity at birth affects ischemic injury and recovery, and that the consequences of neonatal…”
Get full text